Hillstream BioPharma (HILS) Short Interest Ratio & Short Volume

Short interest is the volume of Hillstream BioPharma shares that have been sold short but have not yet been closed out or covered. As of August 31st, traders have sold 52,700 shares of HILS short. 0.42% of Hillstream BioPharma's shares are currently sold short. Learn More on Hillstream BioPharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.42% of Hillstream BioPharma's floating shares are currently sold short.

Hillstream BioPharma saw a decrease in short interest in August. As of August 31st, there was short interest totaling 52,700 shares, a decrease of 17.8% from the previous total of 64,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Hillstream BioPharma currently has issued a total of 17,603,000 shares. Some of Hillstream BioPharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Hillstream BioPharma currently has a public float of 12,490,000 shares.

0.42% of Hillstream BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Hillstream BioPharma: Leap Therapeutics, Inc. (11.30%), Affimed (5.29%), Equillium, Inc. (1.10%), BioVie Inc. (6.44%), GlycoMimetics, Inc. (3.34%), Moleculin Biotech, Inc. (3.32%), TherapeuticsMD, Inc. (1.29%), ProPhase Labs, Inc. (6.76%), Bolt Biotherapeutics, Inc. (1.24%), NextCure, Inc. (0.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.69 billion), Canadian Natural Resources Limited ($3.67 billion), T-Mobile US, Inc. ($3.56 billion), Suncor Energy Inc. ($3.20 billion), Occidental Petroleum Co. ($3.19 billion), Celsius Holdings, Inc. ($2.09 billion), Tractor Supply ($2.08 billion), Moderna, Inc. ($2.04 billion), Royal Caribbean Cruises Ltd. ($2.00 billion), and Rivian Automotive, Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling HILS is an investing strategy that aims to generate trading profit from Hillstream BioPharma as its price is falling. HILS shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Hillstream BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HILS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HILS, twice per month. The most recent reporting period available is August, 31 2023.